Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025

Madrigal Pharmaceuticals to announce Q1 2025 financial results on May 1, followed by a webcast with management.

Quiver AI Summary

Madrigal Pharmaceuticals, Inc. announced that it will release its first-quarter 2025 financial results on May 1, 2025, before the U.S. markets open. Following the announcement, the company's management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operational results, which will be accessible through their Investor Relations website. Madrigal focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), and its medication Rezdiffra is the first FDA-approved treatment for MASH with moderate to advanced fibrosis. Currently, a Phase 3 trial is underway to evaluate Rezdiffra for treating compensated MASH cirrhosis.

Potential Positives

Madrigal Pharmaceuticals will release its first-quarter 2025 financial results, demonstrating transparency and accountability to investors.
The company is hosting a live webcast to review its financial and operating results, providing stakeholders with direct access to management insights.
Madrigal's medication, Rezdiffra, is the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis, emphasizing the company’s leadership in addressing high unmet medical needs.
An ongoing Phase 3 outcomes trial for Rezdiffra in treating compensated MASH cirrhosis indicates the company is actively advancing its product pipeline.

Potential Negatives

There is uncertainty regarding the upcoming financial results for Q1 2025, which may lead to investor apprehension if the results do not meet expectations.
The press release does not provide any financial guidance or projections, leaving investors unclear about the company's future performance.
The mention of ongoing trials highlights potential risks associated with regulatory approval and market acceptance of their product, Rezdiffra.

FAQ

When will Madrigal Pharmaceuticals release its Q1 2025 financial results?

Madrigal Pharmaceuticals will release its Q1 2025 financial results on Thursday, May 1, 2025.

How can I access the live webcast for the financial results?

The live webcast can be accessed in the Investor Relations section of the Madrigal Pharmaceuticals website.

What time is the live webcast scheduled?

The live webcast will begin at 8 a.m. Eastern Time on May 1, 2025.

What is Rezdiffra and its purpose?

Rezdiffra (resmetirom) is a medication for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.

Who should I contact for investor or media inquiries?

For investor inquiries, contact Tina Ventura at [email protected], and for media inquiries, reach out to Christopher Frates at [email protected].

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$MDGL Insider Trading Activity

$MDGL insiders have traded $MDGL stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.

Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:

FRED B CRAVES has made 0 purchases and 17 sales selling 22,470 shares for an estimated $7,408,629.
ROBERT E. WALTERMIRE (Senior VP, Chief Pharma Dev.) has made 0 purchases and 13 sales selling 15,885 shares for an estimated $5,390,968.
RICHARD S LEVY has made 0 purchases and 5 sales selling 10,000 shares for an estimated $3,254,703.
CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 2,869 shares for an estimated $932,208.
MARDI DIER (SVP and CFO) has made 0 purchases and 3 sales selling 2,219 shares for an estimated $720,592.
REBECCA TAUB (Pres., R&D, and CMO) has made 0 purchases and 2 sales selling 2,337 shares for an estimated $679,025.
WILLIAM JOHN SIBOLD (President and CEO) sold 1,584 shares for an estimated $531,020
SHANNON T KELLEY (General Counsel) has made 0 purchases and 2 sales selling 692 shares for an estimated $214,759.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MDGL Hedge Fund Activity

We have seen 151 institutional investors add shares of $MDGL stock to their portfolio, and 111 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 371,771 shares (+inf%) to their portfolio in Q4 2024, for an estimated $114,717,377
JANUS HENDERSON GROUP PLC removed 269,766 shares (-10.9%) from their portfolio in Q4 2024, for an estimated $83,241,694
BRAIDWELL LP removed 183,818 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $56,720,720
WOODLINE PARTNERS LP added 162,027 shares (+110.2%) to their portfolio in Q4 2024, for an estimated $49,996,671
PRICE T ROWE ASSOCIATES INC /MD/ removed 144,933 shares (-19.8%) from their portfolio in Q4 2024, for an estimated $44,721,975
UBS GROUP AG added 144,644 shares (+80.1%) to their portfolio in Q4 2024, for an estimated $44,632,799
HOOD RIVER CAPITAL MANAGEMENT LLC added 127,839 shares (+inf%) to their portfolio in Q4 2024, for an estimated $39,447,280

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MDGL Analyst Ratings

Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

H.C. Wainwright issued a "Buy" rating on 01/14/2025

To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.

Full Release

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com .

Investor Contact
Tina Ventura, [email protected]

Media Contact
Christopher Frates, [email protected]